WO2017134617A1 - Procédé de préparation de dasatinib amorphe - Google Patents
Procédé de préparation de dasatinib amorphe Download PDFInfo
- Publication number
- WO2017134617A1 WO2017134617A1 PCT/IB2017/050596 IB2017050596W WO2017134617A1 WO 2017134617 A1 WO2017134617 A1 WO 2017134617A1 IB 2017050596 W IB2017050596 W IB 2017050596W WO 2017134617 A1 WO2017134617 A1 WO 2017134617A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dasatinib
- preparation
- amorphous
- methanol
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present application provides process for the preparation of amorphous form of dasatinib.
- the drug compound having the adopted name "dasatinib” has a chemical name N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-l-piperazinyl]-2-methyl-4- pyridiminyl]amino]-5-thiazolecarboxamide, and is structurally represented by Formula I.
- Dasatinib is sold under the trade name Sprycel®. Dasatinib is an oral dual BCR/ ABL and Src family tyrosine kinases inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatemant and Philadelphia chromosome- positive acute lymphoblasticjeukemia (Ph+ ALL).
- CML chronic myelogenous leukemia
- Ph+ ALL Philadelphia chromosome- positive acute lymphoblasticjeukemia
- the PCT application WO2005077945 discloses several crystalline forms of Dasatinib which are designated as monohydrate, butanol solvate, ethanol solvate, crystalline neat form (N-6) and crystalline neat form (T1H1-7).
- US patent no. 7973045 discloses anhydrous form and various other solvates of dasatinib.
- US '045 also discloses process for the preparation of amorphous dasatinib by evaporating the solvent from the suspension.
- the solvents used in the process were selected from dimethylformamide, 1, 2-dichlorobenzene, propylene glycol, ethylene glycol and glycerole.
- the process suffers from major drawbacks such as high boiling point of solvent and the amount of residual solvents in the product. Such a process is not well suited for use in a large scale commercial preparation.
- US20140343073A1 discloses process for the preparation of amorphous form of dasatinib by milling.
- the inventors of the present invention have surprisingly found a process for the preparation of amorphous dasatinib that eliminates the problems encountered in the process of prior art.
- the present application provides a process for the preparation of amorphous form of dasatinib, comprising the steps of: a) mixing dasatinib in an organic solvent system;
- Figure 1 illustrates the PXRD pattern of amorphous dasatinib, obtained by the process of Example 1.
- Figure 2 illustrates the PXRD pattern of amorphous dasatinib, obtained by the process of Example 2.
- the present application provides a process for the preparation of amorphous form of dasatinib, comprising the steps of: a) mixing dasatinib in an organic solvent system;
- Organic solvent used in step a) may be selected from but not limited to petroleum ether, diispropyl ether, methyl tert-butyl ether, diethyl ether or the like; N,N- dimethylacetamide, methanol, methanol-water, acetone, ethanol, acetonitrile, isopropyl alcohol, n-butanol, N-methyl-pyrrolidine, tetrahydrofuran, dimethyl sulfoxide or N, N- dimethylformamide or mixtures thereof.
- step b) of the process preferably either concentrated HC1 or an organic solution of HC1 is added to the mixture from step a).
- the organic solution of HC1 in step b) is prepared by passing HC1 gas through the organic solvent.
- the organic solvent used in preparing the organic solution of HC1 is selected from the group comprising a C 1 -4 alcohol, ethyl acetate and acetonitrile or mixtures thereof.
- the C 1 -4 alcohol is one or more of methanol, ethanol, isopropanol and n-butanol or mixtures thereof.
- Isolation of the amorphous form may involve methods such as removal of solvent by filtration, distillation under vacuum, spray drying or freeze drying.
- the isolated material may optionally be dried. Drying may be suitably carried out using any equipment such as a gravity oven, tray dryer, vacuum oven, Biichi® Rotavapor®, air tray dryer, fluidized bed dryer, spin flash dryer, flash dryer, and the like. In an embodiment, the drying may be carried out at atmospheric pressure or under reduced pressures. In an embodiment, the drying may be carried out at a temperature of about 120°C, at a temperature of about 115°C, at a temperature of about 110°C or at a temperature of about 105°C. The drying may be carried out for any time periods required for obtaining a desired quality, such as from about 15 minutes to several hours, or longer.
- Example 2 preparation of amorphous dasatinib
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Procédé de préparation de Dasatinib amorphe.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641003815 | 2016-02-03 | ||
| IN201641003815 | 2016-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2017134617A1 true WO2017134617A1 (fr) | 2017-08-10 |
Family
ID=59500621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2017/050596 Ceased WO2017134617A1 (fr) | 2016-02-03 | 2017-02-03 | Procédé de préparation de dasatinib amorphe |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2017134617A1 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019008555A1 (fr) * | 2017-07-07 | 2019-01-10 | Biocon Limited | Formes polymorphes de dasatinib |
| WO2019209908A1 (fr) | 2018-04-25 | 2019-10-31 | Johnson Matthey Public Limited Company | Formes cristallines de dasatinib |
| CN111217807A (zh) * | 2018-11-26 | 2020-06-02 | 安礼特（上海）医药科技有限公司 | 一种达沙替尼无定型及其制备方法 |
| US10799459B1 (en) | 2019-05-17 | 2020-10-13 | Xspray Microparticles Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US10940149B1 (en) | 2018-06-15 | 2021-03-09 | Handa Oncology, Llc | Kinase inhibitor salts and compositions thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009053854A2 (fr) * | 2007-10-23 | 2009-04-30 | Teva Pharmaceutical Industries Ltd. | Polymorphes de dasatinib et leur procédé de préparation |
| CN104327067A (zh) * | 2014-10-11 | 2015-02-04 | 深圳市浩瑞实业发展有限公司 | 无定形达沙替尼的制备方法 |
| WO2015049645A2 (fr) * | 2013-10-04 | 2015-04-09 | Alembic Pharmaceuticals Limited | Procédé perfectionné de préparation de dasatinib |
-
2017
- 2017-02-03 WO PCT/IB2017/050596 patent/WO2017134617A1/fr not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009053854A2 (fr) * | 2007-10-23 | 2009-04-30 | Teva Pharmaceutical Industries Ltd. | Polymorphes de dasatinib et leur procédé de préparation |
| WO2015049645A2 (fr) * | 2013-10-04 | 2015-04-09 | Alembic Pharmaceuticals Limited | Procédé perfectionné de préparation de dasatinib |
| CN104327067A (zh) * | 2014-10-11 | 2015-02-04 | 深圳市浩瑞实业发展有限公司 | 无定形达沙替尼的制备方法 |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020526528A (ja) * | 2017-07-07 | 2020-08-31 | バイオコン・リミテッド | ダサチニブの多形形態 |
| WO2019008555A1 (fr) * | 2017-07-07 | 2019-01-10 | Biocon Limited | Formes polymorphes de dasatinib |
| US11059813B2 (en) | 2017-07-07 | 2021-07-13 | Biocon Limited | Polymorphic forms of Dasatinib |
| WO2019209908A1 (fr) | 2018-04-25 | 2019-10-31 | Johnson Matthey Public Limited Company | Formes cristallines de dasatinib |
| US11440908B2 (en) | 2018-04-25 | 2022-09-13 | Johnson Matthey Public Limited Company | Crystalline forms of dasatinib |
| US11007195B2 (en) | 2018-06-15 | 2021-05-18 | Handa Oncology, Llc | Kinase inhibitor salts, and compositions thereof |
| US12064430B2 (en) | 2018-06-15 | 2024-08-20 | Handa Oncology, Llc | Kinase inhibitor salts and compositions thereof |
| US12064428B2 (en) | 2018-06-15 | 2024-08-20 | Handa Oncology, Llc | Kinase inhibitor salts and compositions thereof |
| US11160805B2 (en) | 2018-06-15 | 2021-11-02 | Handa Onocology, Llc | Kinase inhibitor salts and compositions thereof |
| US11052088B2 (en) | 2018-06-15 | 2021-07-06 | Handa Oncology, Llc | Kinase inhibitor salts, and compositions thereof |
| US10940149B1 (en) | 2018-06-15 | 2021-03-09 | Handa Oncology, Llc | Kinase inhibitor salts and compositions thereof |
| CN111217807A (zh) * | 2018-11-26 | 2020-06-02 | 安礼特（上海）医药科技有限公司 | 一种达沙替尼无定型及其制备方法 |
| US10869837B1 (en) | 2019-05-17 | 2020-12-22 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US10894017B1 (en) | 2019-05-17 | 2021-01-19 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US10894018B1 (en) | 2019-05-17 | 2021-01-19 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US10874614B1 (en) | 2019-05-17 | 2020-12-29 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US11344500B2 (en) | 2019-05-17 | 2022-05-31 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US10874613B1 (en) | 2019-05-17 | 2020-12-29 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US11833249B2 (en) | 2019-05-17 | 2023-12-05 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US10869836B1 (en) | 2019-05-17 | 2020-12-22 | Xspray Pharma Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| US10799459B1 (en) | 2019-05-17 | 2020-10-13 | Xspray Microparticles Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017134617A1 (fr) | Procédé de préparation de dasatinib amorphe | |
| RU2018120728A (ru) | Лечение остеоартрита | |
| RU2018145948A (ru) | Кристалл пирролопиримидина для получения jak-ингибитора | |
| EP2535339A1 (fr) | Polymorphes du dasatinib, leurs procédés de préparation et leurs compositions pharmaceutiques | |
| AU2016260279B2 (en) | Crystals of azabicyclic compound | |
| WO2005095379B1 (fr) | Sels d'addition d'acide methanesulfonique cristallins derives de l'imatinib | |
| JP7797486B2 (ja) | 新規なｒｈｏ関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| KR20120055571A (ko) | 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸 | |
| AU2014259029B2 (en) | Polymorphic forms of nilotinib hydrochloride | |
| CN102453024B (zh) | 一种尼罗替尼盐酸盐晶型及其制备方法 | |
| KR101774861B1 (ko) | 퓨린 유도체의 사이클로프로판카르복실레이트 에스터 | |
| EP3842434B1 (fr) | Polymorphe cristallin de chlorhydrate de 8-bromo-2-(1-méthylpipéridin-4-ylamino)-4-(4-phénoxyphénylamino)pyrido[4,3-d]pyrimidin-5(6h)-one et procédé de préparation associé | |
| CN107151250A (zh) | 嘧啶类七元环化合物、其制备方法、药用组合物及其应用 | |
| CA2658404A1 (fr) | Antagonistes selectifs des recepteurs de l'adenosine a2a | |
| CN113416181B (zh) | 喹唑啉类衍生物及其用途 | |
| WO2004089948A1 (fr) | Nouvelles formes cristallines d'hydrochlorure de ziprasidone | |
| WO2011080651A2 (fr) | Formes polymorphes de fébuxostat | |
| CN103360326B (zh) | 吉非替尼晶型i的精制方法 | |
| US10392417B2 (en) | Polymorph of regadenoson and process for preparation thereof | |
| CN105503854A (zh) | 一种达沙替尼无水合物的新晶型物及其制备方法 | |
| WO2016001844A1 (fr) | Forme amorphe de dimaléate d'afatinib | |
| AU2012354150A1 (en) | Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof | |
| WO2014009970A2 (fr) | Dispersion solide de linagliptine | |
| WO2017077551A2 (fr) | Esylate nintedanib amorphe et sa dispersion solide | |
| WO2011107911A1 (fr) | Polymorphe d'acide 2-[3-cyano-4-(2-méthylpropoxy) phényl]-4-méthylthiazole-5-carboxylique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17747095 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17747095 Country of ref document: EP Kind code of ref document: A1 |